Rapamycin With Grapefruit Juice for Advanced Malignancies

Inclusion Criteria

• •Histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.
• •Patients with hematologic malignancies (lymphoma, multiple myeloma and chronic lymphocytic leukemia (CLL) only) are eligible to participate in the phase IB portion of the trial only.
• •At least 4 weeks since prior chemotherapy or radiation therapy
• •Aged 18 years or older
• •ECOG performance status 0-2
• •Life expectancy of greater than 3 months.
• •Normal organ and marrow function:
• •* No transfusions of packed red blood cells within 1 week of starting treatment
• •* Leukocytes greater or equal to 3,000/μL
• •\*\* White blood cell (WBC) greater or equal to 1,500/μL for patients with hematologic malignancies
• •* Absolute neutrophil count (ANC) greater or equal to 1,500/μL
• •\*\* ANC greater or equal to 1,000/μL for patients with hematologic malignancies
• •* Platelets (PLT) greater or equal to 100,000/μL
• •\*\* PLT greater or equal to 50,000/μL for patients with hematologic malignancies
• •* Total bilirubin within normal institutional limits
• •* AST (SGOT) and ALT (SGPT) less than or equal to 2.5 times institutional upper limit of normal
• •* Serum triglycerides less than or equal to 500 mg/dl
• •* Creatinine within normal institutional limits OR creatinine clearance greater or equal to 60 mL/min for patients with creatinine levels above institutional normal
• •Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence)
• •Ability to understand and the willingness to sign a written informed consent document.